Engimmune Therapeutics raises CHF 15.5 million in seed financing to develop novel T-cell receptor therapeutics

  • Financing co-led by Pureos Bioventures and Novo Holdings with incubation from BaseLaunch
  • Proceeds will be used to develop next-generation T-cell receptor-based therapies for cancer treatment
  • TCR therapy pioneer and industry veteran Dr Bent Jakobsen appointed as Chairman of the Board

Basel, Switzerland, May 3, 2022. Engimmune Therapeutics AG (“Engimmune”), a Swiss biotech company developing novel T-cell receptor (TCR)-based therapeutics, announced today the completion of a CHF 15.5 million (EUR 15.2 m / USD 16.7 m) seed financing round, co-led by Pureos Bioventures and Novo Holdings.

Read more

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...

GET IN TOUCH